PR Newswire
CALGARY, Dec. 6, 2016
CALGARY, Dec. 6, 2016 /PRNewswire/ - Oncolytics
Biotech® Inc. ("Oncolytics" or the "Company") (TSX: ONC) (OTCQX: ONCYF) today announced that Dr. Brad Thompson has resigned from Oncolytics board of directors effective immediately.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of
oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage,
randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For
further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended,
and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities
laws. Statements, other than statements of historical facts, included in this press release that address activities, events or
developments that Oncolytics expects or anticipates will or may occur in the future, including the impact on Oncolytics and its
clinical program of the change in Oncolytics board of directors, and other such matters are forward-looking statements and
forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties
include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient
groups, the availability of funds and resources to pursue research and development projects, the efficacy of
REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside a controlled
test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
REOLYSIN®, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statements and forward-looking
information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking
information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as
required by applicable laws.
SOURCE Oncolytics Biotech Inc.